SOBI: Swedish Orphan Biovitrum AB is dedicated to developing innovative treatments for rare diseases, focusing primarily on areas such as Haematology, Immunology, and Specialty Care. The company recognizes that only a small percentage of rare diseases have approved medicines, highlighting the urgent need for new therapies. SOBI's research and development (R&D) efforts are concentrated on late-stage research, aiming to bring new treatments to market while also expanding existing products into new indications and regions. This approach not only addresses unmet medical needs but also emphasizes the importance of gathering real-world evidence to support the efficacy and safety of their therapies.

The company’s commitment to patient access is evident in its structured pipeline and various programs, including Investigator Sponsored Studies and Managed Access Programs. These initiatives are designed to facilitate the availability of innovative treatments to patients who need them most, despite the inherent complexities and risks associated with drug development. By prioritizing patient-centric approaches and focusing on the unique challenges posed by rare diseases, SOBI aims to transform the lives of individuals affected by these conditions, ensuring that they receive the care and treatment they deserve.

Sweden

Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. We provide sustainable access to innovative therapies in the areas of haematology, immunology, and specialty indications. Today, we employ approximately 1,800 people across Europe, North America, the Middle East and Asia. In 2023, our revenue amounted to SEK 22.1 billion. The Sobi share (STO:SOBI) is listed on Nasdaq Stockholm. You can find more information about Sobi at sobi.com. 

SOBI: Swedish Orphan Biovitrum AB

Company Details